Citius Pharmaceuticals, Inc. (CTXR) financial statements (2022 and earlier)

Company profile

Business Address 11 COMMERCE DRIVE
CRANFORD, NJ 07016
State of Incorp. NV
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments65,42170,07313,8607,8949,1843,204294
Cash and cash equivalents65,42170,07313,8607,8949,1843,204294
Receivables    818  
Prepaid expense2,5242,7411224858220598
Total current assets:67,94572,81413,9827,94210,0603,424893
Noncurrent Assets
Operating lease, right-of-use asset7808239861,138
Property, plant and equipment6721134
Intangible assets, net (including goodwill)9,3479,3479,3471,5871,5871,5871,587
Goodwill9,3479,3479,3471,5871,5871,5871,587
Other undisclosed noncurrent assets59,43859,43819,45718,31919,40219,40219,467
Total noncurrent assets:69,57169,61529,79221,04420,99020,99221,058
TOTAL ASSETS:137,516142,42943,77428,98631,05124,41721,950
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,1603,8053,7654,4353,0122,2692,801
Accounts payable1,7891,2771,8562,7141,573602909
Accrued liabilities3,137622164246182561958
Employee-related liabilities2,2341,9061,6551,4011,1991,063903
Interest and dividends payable  9074584231
Debt  173173173173 
Derivative instruments and hedges, liabilities      1,682
Due to related parties     2828
Other undisclosed current liabilities182177159   673
Total current liabilities:7,3423,9824,0974,6083,1852,4695,184
Noncurrent Liabilities
Long-term debt and lease obligation6316781,020    
Long-term debt, excluding current maturities  165    
Operating lease, liability631678855 
Liabilities, other than long-term debt4,9864,9864,986    
Deferred income tax liabilities4,9864,9864,986 
Total noncurrent liabilities:5,6175,6646,006    
Total liabilities:12,9589,64610,1034,6083,1852,4695,184
Stockholders' equity
Stockholders' equity attributable to parent123,958132,18233,67124,37927,86621,94716,766
Common stock146146562916873
Additional paid in capital229,085228,084104,20980,17068,10749,66034,029
Accumulated deficit(105,273)(96,048)(70,594)(55,820)(40,258)(27,721)(17,336)
Stockholders' equity attributable to noncontrolling interest600600     
Total stockholders' equity:124,558132,78333,67124,37927,86621,94716,766
TOTAL LIABILITIES AND EQUITY:137,516142,42943,77428,98631,05124,41721,950

Income statement (P&L) ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Revenues909011090818  
Other operating income    818  
Other income6060110    
Cost of revenue
(Cost of Goods and Services Sold)
    (75)(50) 
Gross profit:909011090743(50) 
Operating expenses(24,635)(23,532)(17,711)(15,598)(13,789)(9,986)(7,449)
Other undisclosed operating income (loss)(180)(90)(110)(90)(743)50 
Operating loss:(24,725)(23,532)(17,711)(15,598)(13,789)(9,986)(7,449)
Nonoperating income (expense)502477163361,253(399)(846)
Investment income, nonoperating2822626853   
Debt instrument, convertible, beneficial conversion feature    1,5951,595 
Other nonoperating income      460
Interest and debt expense329322(16)(16)450(851)(5)
Loss from continuing operations before equity method investments, income taxes:(23,894)(22,732)(17,564)(15,579)(12,087)(11,236)(8,301)
Other undisclosed income (loss) from continuing operations before income taxes  1631,141(450)8515
Income (loss) from continuing operations before income taxes:(23,894)(22,732)(17,548)15,562(12,537)(10,385)(8,296)
Income tax expense(2)(1)     
Income (loss) before gain (loss) on sale of properties:(23,896)(22,733)(17,548)15,562(12,537)(10,385)(8,296)
Other undisclosed net loss(316)(321) (31,124)   
Net loss:(24,212)(23,054)(17,548)(15,562)(12,537)(10,385)(8,296)
Other undisclosed net income attributable to parent79      
Net loss attributable to parent:(24,133)(23,054)(17,548)(15,562)(12,537)(10,385)(8,296)
Preferred stock dividends and other adjustments(1,451)(1,451)     
Net loss available to common stockholders, diluted:(25,584)(24,505)(17,548)(15,562)(12,537)(10,385)(8,296)

Comprehensive Income ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Net loss:(24,212)(23,054)(17,548)(15,562)(12,537)(10,385)(8,296)
Comprehensive loss, net of tax, attributable to parent:(24,212)(23,054)(17,548)(15,562)(12,537)(10,385)(8,296)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: